Get the Stockscreener App
13.27
7.71%
0.95
After Hours:
13.46
0.19
+1.43%
Tenax Therapeutics Inc stock is traded at $13.27, with a volume of 441.55K.
It is up +7.71% in the last 24 hours and up +37.51% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$12.32
Open:
$12.5
24h Volume:
441.55K
Relative Volume:
3.18
Market Cap:
$82.85M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.7889
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+10.58%
1M Performance:
+37.51%
6M Performance:
+128.40%
1Y Performance:
+111.31%
1-Day Range:
$12.19
$13.41
1-Week Range:
$10.94
$13.85
52-Week Range:
$4.63
$14.22
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
13.27 | 76.92M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Precision Trading with Tenax Therapeutics Inc. (TENX) Risk Zones - Stock Traders Daily
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Tenax Therapeutics Inc. (TENX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Tenax Therapeutics Inc. (TENX) Affects Rotational Strategy Timing - Stock Traders Daily
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Tenax Therapeutics (TENX) Price Target Increased by 12.22% to 25.76 - Nasdaq
Will Tenax Therapeutics Inc. stock see insider buying2025 Trading Recap & Verified High Yield Trade Plans - DonanımHaber
Is Tenax Therapeutics Inc. stock near bottom after declineWeekly Trade Report & Safe Capital Growth Tips - DonanımHaber
Is Tenax Therapeutics Inc. stock overvalued by current metricsJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - DonanımHaber
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX) - The Globe and Mail
Is Tenax Therapeutics Inc. stock supported by strong cash flowsMarket Movers & Low Drawdown Investment Ideas - DonanımHaber
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Can Tenax Therapeutics Inc. stock beat market expectations this quarter2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Guggenheim Maintains Tenax Therapeutics (TENX) Buy Recommendation - Nasdaq
Tenax Therapeutics’ phase 3 LEVEL study confirms enrollment target By Investing.com - Investing.com Canada
[8-K] TENAX THERAPEUTICS, INC. Reports Material Event | TENX SEC FilingForm 8-K - Stock Titan
Tenax Therapeutics (TENX) Updates on Clinical Trials and New Ini - GuruFocus
Tenax Therapeutics’ phase 3 LEVEL study confirms enrollment target - Investing.com
Tenax Therapeutics level trial on track to complete enrollment in H1 2026 - marketscreener.com
Tenax Therapeutics Confirms Enrollment Target for LEVEL Study; Initiates LEVEL-2 Phase 3 Study for TNX-103 - Quiver Quantitative
Tenax Therapeutics Level Trial On Track To Complete Enrollment In H1 2026 - TradingView — Track All Markets
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - The Manila Times
Heart failure drug trials expand as Tenax starts second Phase 3 study - Stock Titan
Tenax Therapeutics stock price target raised to $25 from $14 at Guggenheim - Investing.com Canada
Tenax Therapeutics (TENX): Analyst Raises Target Price to $25 | - GuruFocus
Growth Report: Is YETI stock recession proof2025 Buyback Activity & Safe Entry Zone Tips - moha.gov.vn
Discipline and Rules-Based Execution in TENX Response - Stock Traders Daily
Tenax Therapeutics Earnings Notes - Trefis
What analysts say about Tenax Therapeutics Inc stockCovered Call Writing & Build Winning Strategies With Zero Cost - earlytimes.in
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Insider Stuart Rich Buys 2,500 Shares - MarketBeat
Tenax Therapeutics director Rich Stuart buys $50,792 in stock By Investing.com - Investing.com South Africa
Tenax Therapeutics director Rich Stuart buys $50,792 in stock - Investing.com
Officer/Dir Rich Buys 5,000 ($50.8K) Of Tenax Therapeutics Inc [TENX] - TradingView — Track All Markets
TENAX Therapeutics CMO Stuart Rich Acquires 5,000 Shares - TradingView — Track All Markets
Tenax Therapeutics (NASDAQ:TENX) Insider Stuart Rich Buys 1,500 Shares - MarketBeat
Officer/Dir Rich Buys 5,000 ($45.6K) Of Tenax Therapeutics Inc [TENX] - TradingView
What technical signals suggest for Tenax Therapeutics Inc. stock2025 Macro Impact & Short-Term High Return Strategies - Newser
Behavioral Patterns of TENX and Institutional Flows - Stock Traders Daily
Why Tenax Therapeutics Inc. stock could benefit from AI revolution2025 Trading Volume Trends & Comprehensive Market Scan Insights - Newser
Financial Analysis: Mainz Biomed (NASDAQ:MYNZ) vs. Tenax Therapeutics (NASDAQ:TENX) - Defense World
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
What analysts say about Tenax Therapeutics Inc. stockMean Reversion Trades & Market-Leading Growth Rates - earlytimes.in
Tenax Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Tenax Therapeutics (Nasdaq: TENX) plans Dec. 2 and 4 fireside chats at Evercore, Piper - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
(TENX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
GIORDANO CHRISTOPHER THOMAS Insider Trades - Nasdaq
Is Tenax Therapeutics Inc. stock a safe buy before earningsEarnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):